[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368166-105":59,"doc-detail-368166-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","integrated-cancer-cell-specific-single-cell-rna-seq-datasets-of-immune-checkpoint-blockade-treated-patients","Integrated cancer cell-specific single-cell RNA-seq datasets of immune checkpoint blockade-treated patients","","Immune checkpoint blockade therapies show variable efficacy across patients and cancer types. To address limitations of existing single-cell RNA-seq studies, the work compiles eight scRNA-seq datasets spanning nine cancer types and covering 223 patients, including 90,270 cancer cells and 265,671 other cell types. The resource is curated, quality-checked, pre-processed, and analyzed to enable standardized cross-study exploration. User-friendly interfaces and shared code/data support accessible investigation of cancer cell responses to ICB treatment.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/integrated-cancer-cell-specific-single-cell-rna-seq-datasets-of-immune-checkpoint-blockade-treated-patients/368166/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/integrated-cancer-cell-specific-single-cell-rna-seq-datasets-of-immune-checkpoint-blockade-treated-patients/368166.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the compiled scRNA-seq resource address?","Question",{"text":112,"@type":113},"Existing ICB single-cell studies are often limited by sample size and computational barriers, and bulk RNA-seq lacks resolution for cancer cell-specific response analysis. The resource aggregates standardized scRNA-seq datasets for easier cross-cancer exploration.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many datasets, patients, and cell types are included?",{"text":117,"@type":113},"The compilation includes eight scRNA-seq datasets from nine cancer types, covering 223 patients, 90,270 cancer cells, and 265,671 other cell types.",{"name":119,"@type":110,"acceptedAnswer":120},"What steps were used to prepare the datasets for reuse?",{"text":121,"@type":113},"The data were meticulously curated, quality-checked, pre-processed, and analyzed. Standardization and merging across studies enable consistent downstream exploration.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368166,1790448369,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","[www. nature.com/scientificdata](www. nature.com/scientificdata)  \nopeN  \nData DeSCRIptoR  \nIntegrated cancer cell-specific single-cell RNa-seq datasets of immune checkpoint blockade-  \ntreated patients  \nMahnoor N. Gondal 1,2, Marcin Cieslik1,2,3,4 ✉ & arul M. Chinnaiyan1,2,3,4,5,6 ✉  \nImmune checkpoint blockade (ICB) therapies have emerged as a promising avenue for the treatment of various cancers. Despite their success, the efficacy of these treatments is variable across patients and cancer types. Numerous single-cell RNa-sequencing (scRNa-seq) studies have been conducted to unravel cell-specific responsesto ICB treatment. However, these studies are limited in their sample sizes and require advanced coding skills for exploration. Here, we have compiled eight scRNA-seq datasets from nine cancer types, encompassing 223 patients, 90,270 cancer cells, and 265,671 other cell types. This compilation forms a unique resource tailored to investigate how cancer cells respond to ICB treatment across cancer types. We meticulously curated, quality-checked, pre-processed, and analyzed the data, ensuring easy access for researchers. Moreover, we designed a user-friendly interface for seamless exploration. By sharing the code and data for creating these interfaces, we aim to assist fellow  \nresearchers. These resources offer valuable support to those interested in leveraging and exploring single-cell datasets across diverse cancer types, facilitating a comprehensive understanding of ICB responses.  \nBackground & Summary  \nThe cytotoxic activity of T cells can be deactivated through interaction between checkpoint proteins such as PD-1 found on the surface ofT cells, and their counterparts, like PD-L1 or PD-L1, present on cancerous cells1. As a result, many cancer cells hijack this mechanism by overexpressing ligands such as PD-L1, disrupting the body’s immune response and impeding the T cells’ ability to eradicate cancer cells1. Research into understanding cancer immune evasion led to the development of immune checkpoint blockade (ICB) therapy that includes monoclonal antibodies that block checkpoint proteins’ functions, allowing activated cytotoxic T cells to eliminate cancer cells2–4. While such therapies have shown promise in treating different cancer types, their efficacy varies among individual patients and specific cancer types5–14. Numerous studies have attempted to uncover the factors contributing to the success or failure ofICB therapies, predominantly employing RNA expression data15–21. However, due to the multifactorial intrinsic properties of cancer cells, conventional bulk RNA sequencing lacks the resolution needed for an in-depth exploration of cancer cell-specific responses to ICB treatment.  \nSingle-cell RNA-sequencing (scRNA-seq) provides a unique opportunity to dissect the intricate landscape of cancer cell-specific responses to ICB treatment. Numerous scRNA-seq studies have explored patients treated with ICB across various cancer types, including skin cancers such as melanoma22–25, and basal cell carcinoma26. Additionally, investigations have extended to breast cancer subtypes like triple negative27, HER2-positive27, ER-positive27, as well as kidney cancer, specifically clear cell renal carcinoma28, and liver cancers such as hepatocellular carcinoma29, intrahepatic cholangiocarcinoma29. Single-cell studies investigating ICB-treated patients have provided valuable insights into the cellular responses to immune checkpoint blockade therapies, potentially unveiling novel biomarkers30. However, these studies often are limited in their sample size and the inherent  \n1Department of computational Medicine & Bioinformatics, University of Michigan, Ann Arbor, Mi, USA. 2Michigan center for translational Pathology, University of Michigan, Ann Arbor, Mi, USA. 3 Department of Pathology, University of Michigan, Ann Arbor, Mi, USA. 4 University of Michigan Rogel cancer center, Ann Arbor, Mi, USA. 5Department of Urology, University of Mic","cbCaikeewMkxKG4f","https://ap.wps.com/l/cbCaikeewMkxKG4f","pdf",4591690,12,"English","# Background & Summary\n## ICB mechanism and need for cell-resolution data\n## Scope of compiled scRNA-seq datasets\n## Data curation, quality control, and preprocessing\n## Interfaces for exploration and accessibility\n## Standardized normalization using stable expressed genes","[{\"question\":\"What problem does the compiled scRNA-seq resource address?\",\"answer\":\"Existing ICB single-cell studies are often limited by sample size and computational barriers, and bulk RNA-seq lacks resolution for cancer cell-specific response analysis. The resource aggregates standardized scRNA-seq datasets for easier cross-cancer exploration.\"},{\"question\":\"How many datasets, patients, and cell types are included?\",\"answer\":\"The compilation includes eight scRNA-seq datasets from nine cancer types, covering 223 patients, 90,270 cancer cells, and 265,671 other cell types.\"},{\"question\":\"What steps were used to prepare the datasets for reuse?\",\"answer\":\"The data were meticulously curated, quality-checked, pre-processed, and analyzed. Standardization and merging across studies enable consistent downstream exploration.\"}]","Integrated cancer cell-specific single-cell RNA-seq datasets of immune checkpoint blockade-treated patients | PDF",1790175390,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f8fff61d1ec21214b8658ba3592ad3d.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/befe02b2323ba9f1262712149b8b43a9.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/be0493915a10c82d7c5fa98e1961aea0.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ccf512972f83293a468b41ccf6cc500c.webp",980,1287]